Womble Bond Dickinson’s life sciences and pharmaceutical attorneys are committed to providing effective and practical advice to clients at the intersection of pharmaceutical law and innovation. Our multidisciplinary team of professionals has experience working alongside a myriad of companies within this diverse industry, including pharmaceutical, biotechnology, medical device, animal health, biodefense and other life sciences sectors.
Our professionals have deep knowledge of the complex and highly specialized life sciences industry, with many having served as former in-house counsel and scientists at life sciences and pharmaceutical companies, as well as former patent examiners and FDA regulators. This experience allows us to understand the scientific foundation of life sciences businesses and to provide efficient analysis and advice tailored to the specific needs of our clients.
Led by one of the industry’s most respected litigation teams, we counsel international, innovator pharmaceutical companies and represent them in district courts across the United States, the Federal Circuit, and before the USPTO. We also have extensive experience with Abbreviated New Drug Application (ANDA) litigation and inter partes proceedings.
Pharmaceutical Law Services
With in-depth knowledge of pharmaceutical law and access to a wider transatlantic team of professionals experienced in patent law, trademarks, licensing, litigation, regulatory law and more, we are dedicated to providing sector-specific advice to clients throughout the life cycle of their business.
Our life sciences and pharmaceutical law services include:
Patent preparation and prosecution, investigations and portfolio management
Intellectual property transactions, including complex licensing and a broad range of corporate and commercial agreements
Trademarks and brand management, copyrights, and data protection
Intellectual property litigation, including ANDA litigation
Corporate transactions, including mergers and acquisitions, joint ventures, and strategic alliances
FDA regulatory advice surrounding biologics, drugs, medical devices as well as cutting-edge biosimilars and regenerative therapies
Products litigation involving pharmaceutical and life sciences products
Pharmaceutical government contracts and regulations.
We understand the challenges life sciences and pharmaceutical companies face daily, including protecting valuable innovations and adhering to ever-changing government regulations. Our team is well-positioned to help clients navigate the challenges and take advantage of the endless opportunities for growth within this important sector.
Successfully defended a European-based pharmaceutical company in a patent litigation under the Hatch-Waxman Act for patents covering a gastrointestinal product. The multi-region Life Sciences Litigation team successfully initiated this ANDA case and narrowed the issues to infringement. At bench trial our client won on all issues
Represented a client in the opioid space in the procurement of multiple Orange Book listed patents protecting its products to 2031. Successfully defended a challenge in an Inter Partes Review of one of these patents where all claims were confirmed as valid
Represented a gene-therapy company in the global licensing and commercialization of its rAAV gene therapy technology for the treatment of rare diseases including two technology spin-out transactions involving exclusive licenses to two different large, multinational pharmaceutical companies with an aggregate deal value of up to $1 billion
Secured dismissal of a federal products liability case on behalf of a large pharmaceutical company headquartered in the UK with a significant presence in the US. The plaintiff’s complaint was over a migraine drug and its alleged side effects. After voluntary disclosure of medical records, the team was able to persuade plaintiff’s counsel that continuing litigation would not be fruitful, and the case was dismissed before extensive discovery commenced.
UK
Advising a UK based network drug discovery business on pre-IPO funding rounds on its initial public offering on the AIM market and on subsequent secondary fundraisings to raise funds in excess of £100 million
Assisting through local counsel an AIM listed protein engineering company to enter the Chinese market
Sale of UK medical software business to a NYSE listed plc and market leader in complementary analytical technologies
Advising a leading UK based protein engineering business, on seed capital and subsequent fundraisings.
Overview
Overview
Womble Bond Dickinson’s life sciences and pharmaceutical attorneys are committed to providing effective and practical advice to clients at the intersection of pharmaceutical law and innovation.
Our multidisciplinary team of professionals has experience working alongside a myriad of companies within this diverse industry, including pharmaceutical, biotechnology, medical device, animal health, biodefense and other life sciences sectors.
Our services in life sciences and pharmaceutical law
Our professionals have deep knowledge of the complex and highly specialized life sciences industry, with many having served as former in-house counsel and scientists at life sciences and pharmaceutical companies, as well as former patent examiners and FDA regulators. This experience allows us to understand the scientific foundation of life sciences businesses and to provide efficient analysis and advice tailored to the specific needs of our clients.
Led by one of the industry’s most respected litigation teams, we counsel international, innovator pharmaceutical companies and represent them in district courts across the United States, the Federal Circuit, and before the USPTO. We also have extensive experience with Abbreviated New Drug Application (ANDA) litigation and inter partes proceedings.
Pharmaceutical Law Services
With in-depth knowledge of pharmaceutical law and access to a wider transatlantic team of professionals experienced in patent law, trademarks, licensing, litigation, regulatory law and more, we are dedicated to providing sector-specific advice to clients throughout the life cycle of their business.
Our life sciences and pharmaceutical law services include:
Patent preparation and prosecution, investigations and portfolio management
Intellectual property transactions, including complex licensing and a broad range of corporate and commercial agreements
Trademarks and brand management, copyrights, and data protection
Intellectual property litigation, including ANDA litigation
Corporate transactions, including mergers and acquisitions, joint ventures, and strategic alliances
FDA regulatory advice surrounding biologics, drugs, medical devices as well as cutting-edge biosimilars and regenerative therapies
Products litigation involving pharmaceutical and life sciences products
Pharmaceutical government contracts and regulations.
We understand the challenges life sciences and pharmaceutical companies face daily, including protecting valuable innovations and adhering to ever-changing government regulations. Our team is well-positioned to help clients navigate the challenges and take advantage of the endless opportunities for growth within this important sector.
Need legal advice and guidance in life sciences and pharmaceuticals?
Our team is able to help provide solutions to you and your organization. Browse through our lawyers and professional staff to find the right attorney near you.
Examples of our work and how we’ve helped companies of all sizes with a wide range of challenges.
US
Successfully defended a European-based pharmaceutical company in a patent litigation under the Hatch-Waxman Act for patents covering a gastrointestinal product. The multi-region Life Sciences Litigation team successfully initiated this ANDA case and narrowed the issues to infringement. At bench trial our client won on all issues
Represented a client in the opioid space in the procurement of multiple Orange Book listed patents protecting its products to 2031. Successfully defended a challenge in an Inter Partes Review of one of these patents where all claims were confirmed as valid
Represented a gene-therapy company in the global licensing and commercialization of its rAAV gene therapy technology for the treatment of rare diseases including two technology spin-out transactions involving exclusive licenses to two different large, multinational pharmaceutical companies with an aggregate deal value of up to $1 billion
Secured dismissal of a federal products liability case on behalf of a large pharmaceutical company headquartered in the UK with a significant presence in the US. The plaintiff’s complaint was over a migraine drug and its alleged side effects. After voluntary disclosure of medical records, the team was able to persuade plaintiff’s counsel that continuing litigation would not be fruitful, and the case was dismissed before extensive discovery commenced.
UK
Advising a UK based network drug discovery business on pre-IPO funding rounds on its initial public offering on the AIM market and on subsequent secondary fundraisings to raise funds in excess of £100 million
Assisting through local counsel an AIM listed protein engineering company to enter the Chinese market
Sale of UK medical software business to a NYSE listed plc and market leader in complementary analytical technologies
Advising a leading UK based protein engineering business, on seed capital and subsequent fundraisings.
This selection will switch the website from presenting information primarily about the United Kingdom to information about the United States. If you would like to switch back, you may use location selection options at the top of the page.
Contact
Although we would like to hear from you, we cannot represent you until we know that doing so will not create a conflict of interest. Also, we cannot treat unsolicited information as confidential. Accordingly, please do not send us any information about any legal matter until we authorize you to do so. To initiate a possible representation, please call one of our lawyers or staff members.
By clicking the “ACCEPT” button, you agree that we may review any information you transmit to us. You recognize that, even if you submit information that you consider confidential in an effort to retain us, our review of that information will not create an obligation on us to keep it confidential and will not preclude us from representing another client directly adverse to you, even in a matter where that information could and will be used against you.
Please click the “ACCEPT” button if you understand and accept the foregoing statement and wish to proceed.
